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Abstract
Background: Genomic tests are available to predict breast cancer recurrence and to guide clinical decision
making. These predictors provide recurrence risk scores along with a measure of uncertainty, usually a confidence
interval. The confidence interval conveys random error and not systematic bias. Standard tumor sampling methods
make this problematic, as it is common to have a substantial proportion (typically 30-50%) of a tumor sample
comprised of histologically benign tissue. This “normal” tissue could represent a source of non-random error or
systematic bias in genomic classification.
Methods: To assess the performance characteristics of genomic classification to systematic error from normal
contamination, we collected 55 tumor samples and paired tumor-adjacent normal tissue. Using genomic signatures
from the tumor and paired normal, we evaluated how increasing normal contamination altered recurrence risk
scores for various genomic predictors.
Results: Simulations of normal tissue contamination caused misclassification of tumors in all predictors evaluated,
but different breast cancer predictors showed different types of vulnerability to normal tissue bias. While two
predictors had unpredictable direction of bias (either higher or lower risk of relapse resulted from normal
contamination), one signature showed predictable direction of normal tissue effects. Due to this predictable
direction of effect, this signature (the PAM50) was adjusted for normal tissue contamination and these corrections
improved sensitivity and negative predictive value. For all three assays quality control standards and/or appropriate
bias adjustment strategies can be used to improve assay reliability.
Conclusions: Normal tissue sampled concurrently with tumor is an important source of bias in breast genomic
predictors. All genomic predictors show some sensitivity to normal tissue contamination and ideal strategies for
mitigating this bias vary depending upon the particular genes and computational methods used in the predictor.
Keywords: biomarker validation, genomic assays, breast cancer, normal tissue, bias
Background
Breast cancer is well-recognized as a heterogeneous dis-
ease and great progress has been made in the past dec-
ade in classifying tumors for prognosis and prediction
[1-8]. Two different assays are clinically and commer-
cially available for genomic characterization of tumors:
the 21-gene OncotypeDx assay (Genome Health Inc,
Redwood City, CA) for estrogen receptor (ER)-positive,
early stage breast cancer [6,7] and the 70-gene Mamma-
print (Agendia, Huntington Beach, CA) assay [4,5] for
ER-positive and ER-negative early-stage, node-negative
breast cancers. A 50-gene subtype predictor, the PAM50
[8], has been validated for stratifying node-negative
patients according to prognosis and tumor subtype.
Each of these three assays results in a clinically useful
score, with OncotypeDx providing a continuous but
categorizable recurrence score, Mammaprint providing a
dichotomous high risk or low risk categorization, and
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relapse (ROR) score, along with a categorical classifica-
tion of biological subtype. These scores are computed
based on the expression of selected transcripts in a het-
erogeneous tissue sample comprised of varying amounts
of malignant cells, tumor stroma, and histologically nor-
mal breast tissue. The tumor-adjacent normal breast tis-
sue contributes RNA that dilutes the malignant cell
RNA in a sample. Because normal tissue and tumor tis-
sue have markedly different expression patterns [9], this
could be an important source of non-random error in
genomic predictors.
Random error is error due to chance, can be in either
direction, and has been operationally defined as “unex-
plained variation”. This type of error can cause estimates
that vary in either direction and have an average or net
effect of zero [10]. Random error results in imprecision,
but precision can be improved by replication. Non-random
or systematic error is a bias that has a net direction and
magnitude, and importantly, this bias does not diminish
with replication. Systematic error or bias can have magni-
tudes that are as large as or larger than the effect of inter-
est. In the context of genomic predictors, normal tissue
could have effects on gene expression that are similar in
magnitude to differences between subtypes. The bias could
also be in a consistent direction (for example biasing the
predictor toward a lower recurrence risk) or could be
unpredictable with no consistent direction. The magnitude
and direction of normal tissue effects on existing genomic
predictors have not been evaluated.
To investigate how normal tissue contamination of
tumor samples affects genomic predictions, we analyzed 55
samples of breast cancer and paired adjacent normal tissue
from the same patients [9]. By combining signal from nor-
mal and tumor specimens, we performed a sensitivity ana-
lysis, evaluating how normal contamination affected tumor
classifiers. Our results show that depending upon the spe-
cific predictor, the direction of bias was either predictable
(tending in the same direction) or unpredictable. Predict-
able bias allows for correction, and we identified low varia-
bility across normal tissues and high variability across
tumors as a desirable feature of genomic predictors with
predictable bias. We then conducted a sensitivity analysis
of the vulnerability of genomic assays to contamination
bias by applying median normal tissue gene expression
levels in a linear model to adjust for contamination bias,
demonstrating that adjustment for contamination improves
sensitivity and negative predictive value.
Results and Discussion
Effects of normal contamination in tumors with paired
normal tissue
Normal tissue in tumor specimens altered the prediction
of tumor subtype or prognosis. Figure 1 shows that in
55 pairs of tumor and normal tissue, the genomic pre-
diction changed as normal tissue contribution to gene
expression increased. In the case of the PAM50 subtype
predictor (Figure 1A), the samples moved from more
aggressive subtypes to less aggressive subtypes as the
normal contents increased. The same is true of the
ROR-S (Figure 1B). The bias induced by normal con-
tents increased the likelihood of underestimating patient
risk. However, the PAM50 was the only assay that
showed predictable direction of misclassification.
The other two predictors did not show predictable
changes in risk score with increasing percentage normal.
With the 70-gene good/poor prognosis and 21-gene recur-
rence score assays (Figure 1C and 1D respectively), normal
contamination biased subtype classification in either direc-
tion. For example, 9 samples that were classified as good
prognosis using the tumor samples were classified as poor
prognosis as normal percentage increased, while for 11
samples increasing normal changed the prediction from
p o o rt og o o d( F i g u r e1 C ) .T h e2 1 - g e n er e c u r r e n c es c o r e
also caused some samples to move from high to inter-
mediate to low risk, while others moved from low to inter-
mediate to high risk as normal percentage increased
(Figure 1D). There was also substantial variation in the
genomic classification of the 100% histologically normal
tissue. In the final column of Figure 1C and 1D, normal
tissue in the 70-gene signature is called poor prognosis in
67 percent of cases and normal tissue in 21-gene signature
is high or medium risk in 17 percent of cases.
The differences in predictability of bias direction and the
prevalence of high risk phenotype in normal tissue
between the PAM50 and the other predictors can be
explained by qualitative differences in variability of each
gene set across normal samples. Due to the bioinformatics
methods used to develop the PAM50 (i.e. intrinsic subtype
algorithms [2]), the variation and interquartile range for
the PAM50 genes is very low in normal tissues, while it is
high across different tumor specimens (Figure 2A & Addi-
tional File 1, Figure S1). High variation in tumor samples
allows good dynamic range in distinguishing the different
tumor specimens from one another, while the low varia-
tion in the normal samples means that normal tissue con-
tamination tends to lead to similar effects across samples.
Normal tissue appears to have greater variability in the 70-
gene (Figure 2B) and 21-gene assays (Figure 2C), even
showing similar variability to the tumor themselves in the
21-gene assay.
Effects of Normal Contamination in Public Datasets
Biospecimens of histologically normal tissue adjacent to
tumor are rarely available for paired analyses like those
performed in the current study, so a generic or prototypi-
cal normal profile that characterizes the average effect of
normal contamination on tumor predictors could be
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tions to account for normal contamination. It was possible
to define a prototypical normal profile because approxi-
mately 90% of samples had normal-like subtype by the
P A M 5 0a s s a y( s e eF i g u r e1 A )a n ds h o w e dh i g h l yc o r r e -
lated gene expression (93% of correlation coefficients
greater than 0.6) and low variability across normal samples
(Figure 2A). It has previously been reported [11] that a
small percentage of normal tissue adjacent to cancer can
express a profile similar to invasive ductal carcinomas, and
this was also observed in our dataset, but for only a minor-
ity (11%) of samples. We excluded these tumor-like nor-
mal samples in developing a prototypical normal
contamination profile and used 48 normal-like samples to
calculate median gene expression. We compared results
using this median or protypical cancer-adjacent normal to
those obtained using the paired cancer-adjacent normal,
and found that subtype classifications under various nor-
mal contamination scenarios ranging from 0 to 50% are
similar using either the median normal or paired normal
tissue (Additional File 2, Figure S2).
Correcting for normal percentages in application of the
PAM50
The tumor sample profile is a mixture between the
malignant cell profile and its adjacent or contaminating
normal profile. Using the prototypical normal profile to
d e c o n v o l u t et h e s et w op r o f i l e sf o rt h eo n l ya s s a yw i t h
predictable direction of bias (PAM50), we applied Equa-
tion 2 (see Methods) to correct the subtype of 24
patients where the percentage of tumor cells, a,w a s
carefully estimated. Five of the 24 samples had original
normal-like basal-like
HER2-enriched luminal A
luminal B
A.  PAM50 Subtype B.  PAM50 ROR-^ C.  70-gene good/poor D.  21-gene recurrence score
low risk high risk
medium risk
low risk high risk
intermediate risk
good poor
Tumor
100% normal
Tumor
100% normal
Tumor
100% normal
Tumor
100% normal
Figure 1 Tumor classification for the 55 paired normal and tumor samples using (A) PAM50 intrinsic subtype predictor, (B) PAM50
Risk of Recurrence (ROR-S), (C) 70-gene good/poor prognosis signature (Mammaprint), and (D) 21-gene recurrence score predictor
(Oncotype DX). The leftmost column in each panel shows the unadjusted classification, while subsequent columns show the effects of
increasing normal tissue sampled with the tumor. Pure normal tissue gene expression is shown in the right column of each panel. Color coding
is as follows: (A) Normal-like, green; Luminal A, dark blue; Luminal B, light blue; HER2E, magenta; and Basal-like, red (B) PAM50 ROR-S score low-
risk, green; medium-risk, light blue, and high-risk, red (C) Prognosis score: good, green; poor, red. (D) 21-gene assay: low, green; intermediate,
light blue; and high, red.
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rection for percentage normal (Additional File 3, Table
S1). Applying the prototypical normal to these speci-
mens with known percentage tumor did result in
changes to subtype with one normal-like sample (with
90% normal contamination) and 3 Luminal A samples
(with 70%, 30%, and 25% normal) being reclassified as
Luminal B after correction. One Luminal B sample (50%
normal) was reclassified as a Her2-enriched (HER2E)
subtype. Looking at the ROR-S score, 8 of 24 patients
changed in score, with 4 patients switching from Low to
Medium or High risk and 4 patients switching from
Medium to High risk after adjustment. No patients
moved to a less aggressive ROR-S score.
We next turned to three large public datasets to eval-
uate how corrections based on the PAM50 prototypical
normal profile would influence subtype, ROR-S, sensitiv-
ity and negative predictive value. In these larger public
datasets, the true percentage of normal is not known for
individual samples, but tumors were sampled with qual-
ity control criteria that ensured > 50% tumor cellularity
[5], > 70% tumor cellularity [12], or a median percent
tumor cellularity of 60% was reported [13]. We applied
different correction rates from 5 to 30%, 40%, or 50%
(by 5% increment with maximum correction dictated by
the published quality controls in place for each dataset)
across node negative samples and estimated the PAM50
subtype and ROR-S at each normal correction rate.
Table 1 shows that the distribution of subtype and
ROR-S score shifts toward more aggressive subtypes
after adjusting for contaminating normal. In NKI, nor-
mal-like and Luminal A subtypes moved to more
Figure 2 Interquartile range distribution for normal tissue and
paired tumor tissue across three predictors: (A) PAM50, (B) 70-
gene good/poor prognosis, and (C) 16 non-housekeeping genes
in the 21-gene recurrence score (C). The interquartile range
distribution is green for cancer-adjacent normal and red for tumors.
Table 1 Adjusted and unadjusted subtype, ROR-S score
(node negative patients)
Unadjusted, n Adjusted
a,n
NKI
Normal-like 5 2
Luminal A 85 61
Luminal B 18 41
HER2-enriched 14 18
Basal-like 29 29
Low 78 48
Medium 43 49
High 30 54
Naderi et al.
Normal-like 6 2
Luminal A 43 35
Luminal B 15 24
HER2-enriched 11 12
Basal-like 11 13
Low 39 25
Medium 27 33
High 20 28
Wang et al.
Normal-like 15 3
Luminal A 138 58
Luminal B 51 128
HER2-enriched 29 40
Basal-like 53 57
Low 128 39
Medium 85 122
High 73 125
aNKI was adjusted for 30% normal, Naderi et al. was adjusted for 20% normal,
and Wang et al. was adjusted for 10% normal.
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medium risk samples moved to a higher risk class after
adjusting for normal bias. The Luminal B, HER2E,
Basal-like subtypes and ROR-S high risk classes were
most tolerant to normal contamination. The Naderi
et al. [13] and Wang et al. [12] datasets also showed
similar trends toward more aggressive subtypes after
adjusting for normal contamination.
If the true subtype is identifiable by adjusting for normal
contamination, then the sensitivity and negative predictive
value should increase after correction. Figure 3 shows the
change in sensitivity and negative predictive value (NPV)
as a function of correction rate in the NKI, Naderi et al.,
and Wang et al. datasets. In all three datasets, the
sensitivity in detecting patients with relapse-free survival <
5 years increased after adjustment for normal contamina-
tion and the negative predictive value increased. For each
dataset, the maximum % correction shown is consistent
with the maximum percentage of normal allowed (for NKI
and Wang et al.) or the median % normal reported (Naderi
et al.). Sensitivity and negative predictive value are also
given for 10-year and relapse-free survival at the end of
follow up for all three datasets in Additional File 4, Sup-
plementary Data 1 (excel file). In predicting 5-year
relapse-free survival, NPV and sensitivity tended to
increase with increasing normal adjustment.
Different correction rates were needed to attain maxi-
mum NPV with different datasets. This reflects the fact
that contamination rates differed for each of these popula-
tions; different quality control criteria were stated for each
dataset, and the optimum percentage correction correlated
with the stated tumor purity. The NKI dataset had the
most inclusive tumor quality control criteria (> 50% tumor
nuclei) and required the most aggressive corrections (30%
adjustment), while the Naderi et al. dataset with median
60% tumor nuclei required 20% correction and the Wang
et al. dataset had the most stringent quality controls
(> 70% tumor nuclei) and required the least adjustment
(10%). To further confirm that samples with lower con-
tamination rates produce more stable estimates, we used a
fourth public dataset of microdissected samples. This
fourth dataset had too few samples to perform survival
analyses and NPV calculations, but using 48 samples with
> 90% tumor cellularity [14], we applied 5% and 10% nor-
mal correction. As expected, very few samples changed
subtypes with normal correction in this dataset. Only one
sample (2% of samples) changed subtype at 5% normal cor-
rection and four samples (8% of samples) changed at the
more aggressive 10% correction rate. Thus, the misclassifi-
cation evident using normal adjustment was correlated
with reported contamination severity for these datasets.
Normal-contamination correction improves the
relapse-free survival curve separation for node-negative
patients (Figure 4). Unadjusted Kaplan-Meier curves are
shown along with curves adjusted for normal contamina-
tion. Additional File 5, Figure S3 shows overall survival in
node-negative patients from NKI and Naderi et al., but
overall survival was unavailable for the Wang et al. data-
set. Across all of these survival analyses, the qualitative
trends are the same: (1) normal contamination in tumor
specimens causes more aggressive tumors to be misclas-
sified as less aggressive and (2) adjustment for normal
contamination improves negative predictive value.
Conclusions
This paper highlights complex, but fundamental, issues
related to validation of tissue-based genomic biomarkers.
In our assessments of the published methods for several
A - NKI, 5-year relapse-free survival
B - Naderi et al., 5-year relapse-free survival
C - Wang et al., 5-year relapse-free survival
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Figure 3 Sensitivity (dashed line) and negative predictive value
(solid line) at five years for (A) NKI (B) Naderi et al., and (C)
Wang et al. The sensitivity and negative predictive value (NPV) are
plotted as a function of percentage normal correction (equation 2)
with the percentage normal set at 5% increments from 0 to 30-50%.
Sensitivity and NPV were defined in the methods section comparing
low to medium-high (taken together) ROR-S classes from the
PAM50 assay.
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contamination is an important source of bias in genomic
predictors. However, contaminating normal tissue has
different types of impact depending upon the genes
included in the assay. While the 70-gene assay provides
stable results at high tumor percentage, unpredictable
bias occurs when tumor percentage is low (< 70%). The
21-gene assay also showed unpredictable direction of bias
due to contaminating normal. Both of these assays, in
their commercial forms, have implemented quality con-
trol strategies to account for tumor nuclei content. These
strategies appear important given that these assays mis-
classify a large number of non-neoplastic specimens as
more aggressive tumor types. For the PAM50 assay, con-
taminating normal tissue induced predictable and unidir-
ectional changes in subtype. The PAM50 genes have low
variability within normal tissue and distinct expression
between normal and tumor tissue, perhaps because of
A. NKI, unadjusted ROR-S B. NKI, 30% normal-adjusted ROR-S
D. Naderi et al., 20% normal-adjusted ROR-S C. Naderi et al., unadjusted ROR-S
F. Wang et al., 10% normal-adjusted ROR-S E. Wang et al., unadjusted ROR-S
Figure 4 Relapse-free Survival plots for PAM50 ROR-S score given (A) unadjusted NKI data, (B) 30% normal-adjusted NKI data (C)
unadjusted Naderi et al. (D) 20% normal-adjusted Naderi et al. data, (E) unadjusted Wang et al. and (F) 10% normal-adjusted Wang
et al. data. Corrections to the expression assuming a given percentage of tumor (a) were calculated using equation 2. In each figure, the green
line is low ROR-S, the blue line is medium ROR-S, and the red line is high ROR-S.
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genes that had high variation between different tumors
and low variation between different samplings of the
same specimen [2]. To correct for normal contamination
in the PAM50 assay, we calculated the median normal
expression across each of the PAM50 genes and applied
a simple, linear correction to several datasets represent-
ing more than 800 breast cancer patients. Our results
demonstrate that computational approaches adjusting for
normal tissue contamination bias can improve the pre-
dictive value of PAM50 genomic classification.
A few previous studies have attempted to identify gene
expression signatures reflective of pure tumor cells [15-23]
or associated with percentage of stroma in tumor [23].
Other studies have used microdissection to isolate or
enrich for malignant epithelial cells [24]. Our results sug-
gest that identifying genomic predictors that quantitatively
estimate percent normal in tumor specimens is a challen-
ging problem; we were unable to validate previous signa-
tures [23] or identify a new signature that accurately
predicts normal contamination in independent datasets.
Until such a signature is identified and validated, it will
remain difficult to implement correction strategies for
individual patients. However, to illustrate the importance
of the problem we have used public data to conduct a
careful sensitivity analysis of the potential for normal con-
tamination to affect genomic assay results. Our sensitivity
analysis was designed to evaluate a plausible scenario for
the effects of normal contamination, but actual effects of a
given percentage of normal may be over-estimated for
some samples in these datasets. This over-estimation of
the effects could arise from differences in the yield of RNA
per cell between normal and malignant cells [25], such
that histologically evaluated percentage normal does not
correspond linearly with a similar percentage change in
the gene expression. In fact, for the Naderi data where
median tumor cellularity was 60%, only 20% correction
was required, suggesting that normal contamination con-
tributes less RNA per cell, or that the signatures are robust
to some percentage contamination, or both. Pathologic
evaluation of percentage tumor cellularity is also subject
to inter-rater variability. However, by assuming 1:1 yield
between normal and tumor, the current study shows a
plausible worst-case scenario of the biasing effects of a
given percentage of normal tissue and highlights how vul-
nerability may vary across different genomic assays.
Future work should assess the strengths and weaknesses
of various strategies for dealing with normal contamina-
tion, ranging from pathologist review and dissection to
genomic methods for assessing and correcting for normal
bias. Microdissection or other methods for gross dissec-
tion may be necessary for some assays with genes that are
highly variable in normal tissue or stroma. Alternatively,
the development of preanalytic criteria, such as requiring a
minimal percentage of malignant cells in a particular sam-
pling may remain important for ensuring quality results.
The commercial version of the 70 gene assay implements
such preanalytic criteria. One disadvantage of requiring
high levels of tumor nuclei is that some samples will be
excluded. Patients who are likely to be excluded are those
who have small tumors at the time of detection. For some
assays, computational adjustment may obviate the need
for microdissection. For assays with low variation in nor-
mal and predictable direction of effect, pathologist evalua-
tion of percentage tumor remains useful in determining
the likelihood of normal contamination bias or in identify-
ing bounds on correction rates, but less labor intensive
sampling strategies may be possible to minimize the cost
of these assays.
For the PAM50 assay, the tolerance to contamination by
normal tissue is greatest for Luminal B, HER2E, and
Basal-like subtypes or High risk classes. For these assays,
t h et u m o rs i g n a t u r ei ss t i l lstrongly evident at even low
percentages of tumor. The observation of more stable clas-
sification for Basal-like breast cancers coincides with the
recent observation that Basal-like breast cancers are more
robustly identified (relative to other subtypes) in single
sample predictors [26]. Conversely, this also demonstrates
that accurate identification of Luminal A tumors is depen-
dent upon having high malignant cell percentages (i.e. low
levels of normal contamination). The majority of these
erroneously classified Luminal A tumors are Luminal B
after adjustment for normal contamination, suggesting
that Luminal B tumors may “masquerade” as Luminal A
tumors due to the presence of high levels of normal tissue
in the specimen. This observation is particularly important
because misclassification could lead to undertreatment if
this error is not modeled and corrected.
It has been argued that the scientific rigor of transla-
tional biomarker research has lagged behind that of treat-
ment research [27] and that second generation genomic
tests should deal with limitations of the first generation
tests, including the need for higher levels of evidence
[28]. Our results suggest that desirable features of second
generation tests will include attention to important
sources of preanalytic variation in tumor specimens,
including normal contamination and its quantitative
effects in biasing tumor classification. Discussion of these
biases, including direction, magnitude, predictability, and
thorough assessment of the assay sensitivity to these
biases are important considerations. It is not the case
that a given assay is simply resistant or vulnerable to nor-
mal contamination, but rather, the particular genes in an
assay create complex patterns of bias, that must be
further characterized. Other sources of variation in bios-
pecimen processing [29-31] should also be carefully con-
sidered using similar sensitivity analyses. The next
generation of genomic tests for clinical stratification of
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upon the currently available tests by attending to these
important variables.
Methods
Samples and clinical data
We used new data from tumors, tumor-normal pairs,
and public data for this study. The new data on tumor
and tumor-adjacent normal tissue pairs were from
patients undergoing surgery for invasive breast cancer
at UNC Hospitals. We define normal as benign tissue,
whether normal-appearing, reactive, or desmoplastic.
Gene expression microarrays were performed on both
tumor and adjacent normal tissues for 55 tumor-nor-
mal pairs from the same patient, and 24 additional
tumor samples (referred to as UNC24 in tables and
text below) were obtained where tumor cell percentage
was quantified by counting malignant and normal
nuclei in a hematoxylin and eosin (H&E) stained paraf-
fin sections. The H&E stained frozen section was made
from a mirror image tissue specimen immediately adja-
cent to the frozen tissue used for expression analysis.
All of these samples were collected with patient
informed consent by the UNC Lineberger Tissue Pro-
curement Facility under an Institutional Review Board
approved protocol [9]. Public datasets representing
approximately 800 patients and more than 500 node-
negative patients were analyzed for this study, includ-
ing datasets from the Netherlands Cancer Institute
(NKI 295) [5], Nottingham City Hospital NHS Trust
presented in Naderi et al. [13], Erasmus Medical Cen-
ter, Rotterdam, Netherlands Wang et al. [12] and Uni-
versity Hospital La Paz, Madrid Spain as described in
Natrajan et al. [14]. Clinical characteristics of patients
in each dataset are presented in Table 2.
Microarrays
Total RNA was extracted from tumor and paired tumor-
adjacent normal tissue by homogenizing tissue and then
using an RNeasy RNA extraction kit (Qiagen) to isolate
total RNA. RNA quality was assessed using an Agilent
bioanalyzer and only samples with RIN > 7 were used
for subsequent microarrays. Agilent custom 244 k or
catalog 4 × 44 k arrays were performed with linear
amplification and labeling according to manufacturer
protocol. Two-color Agilent protocols were used for all
samples, with Cy3-labeled reference produced from total
RNA from Stratagene Universal Human Reference
(spiked 1:1000 with MCF-7 RNA and 1:1000 with
ME16C RNA to increase expression of breast cancer
genes) and Cy-5 labeled patient specimens. New data
are publicly available through the Gene Expression
Omnibus (GSE22384).
Tumor-Normal Mixing
The impact of increasing proportions of adjacent normal
tissue was assessed for each sample using linear combi-
nations of tumor gene expression and paired normal
gene expression according to the following:
log2

R
G

mixed,i
=l o g 2

R
G

tumor,i
· a +l o g 2

R
G

normal,i
· (1 − a) (1)
where a is the percentage of tumor signal and 1-a is
the percentage of normal signal. Combinations were
made with increments of a equal to 0.10. The assump-
tion that RNA level has a linear and symmetrical influ-
ence on transcript abundance for the PAM50 genes was
tested experimentally. Specifically, expression data from
pure populations of cancer cells grown in monoculture
were linearly combined with expression data from pure
populations of breast fibroblasts; expected expression
values for ratios of epithelium to stroma equal to 3:1,
2:1 or 1:1 were computed. These computed values were
compared to observed gene expression for cocultured
cells where the actual percentage of epithelial content
was 75%, 66% purity, or 50%, respectively. All data for
these analyses are available in the Gene Expression
Omnibus, GSE26411) and described in Camp et al. [32].
Additional File 6, Table S2 shows that the correlations
between observed and computed were high (0.80-0.92)
and that the slopes were very close to 1, suggesting lin-
ear and symmetrical influence of epithelium and stroma
on transcript abundance.
Normalization and Classification with Genomic Predictors
Data were Lowess-normalized and genes that had a sig-
nal of < 10 dpi in either channel were excluded as miss-
ing, and genes that had more than 30% missing data
across all samples were excluded from further analysis.
For genes that passed this filter, missing data were
imputed using 10 nearest neighbors. The following
genomic predictors were applied to these data based on
published methods: the good/poor prognosis signature
of Van’t Veer et al. [4,5] that is currently the basis for
the Mammaprint assay by Agendia, the recurrence score
21-gene assay that is the basis for Oncotype DX [6,7],
and the recurrence risk (ROR-S) and subtype predic-
tions based on the PAM50 assay [8]. The versions of
these assays applied in this paper are based on the pub-
lished scientific literature and may differ from the
patented versions of these assays that are in clinical use.
However, subtle differences between patented and pub-
lished versions of the assay are unlikely to substantially
reduce the validity of the sensitivity analyses performed
in this work.
For the good/poor prognosis predictor we used the set
of probes from the original 70 probes that were available
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Tumor and normal pairs UNC set, known % normal (UNC24) NKI 295 Naderi et al. Wang et al. Natrajan et al.
Patients (n) 55 24 295 135 286 48
Microarrays (n) 118 24 295 307 286 48
Median RFS, months 14 31 78.2 119.5 86 NA
missing RFS, n (%) 33 6 0 1 0 48
Estrogen receptor status, n (%)
positive 35 (63.6) 15 (62.5) 226 (76.6) 93 (68.9) 209 (73.1) 25 (52.1)
negative 18 (32.7) 7 (29.2) 69 (23.4) 40 (29.6) 77 (26.9) 23 (47.9)
missing 2 (3.6) 2 (8.3) 0 (0) 2 (1.5) 0 (0) 0 (0)
AGE, years
mean (standard deviation) 53.2 (13.9) 59.8 (17.0) 44.0 (5.5) 56.9 (8.9) 54 (12) 55 (12.6)
GRADE, n (%)
1 5 (9.1) 2 (8.3) 75 (25.4) 35 (26.0) 7 (2.0) 0 (0)
2 16 (29.1) 7 (29.2) 101 (34.2) 50 (37.0) 42 (15.0) 0 (0)
3 19 (34.5) 14 (58.3) 119 (40.3) 49 (36.3) 148 (52.0) 48 (100.0)
missing 15 (27.3) 1 (4.2) 0 (0) 1 (0.7) 89 (31.0) 0 (0)
TUMOR SIZE, n (%)
< = 2 17 (30.9) 17 (70.8) 155 (52.5) 93 (68.9) 278 (0) 18 (37.5)
> 2 38 (69.1) 6 (25) 140 (47.5) 41 (30.4) 8 (0) 30 (62.5)
missing 0 (0) 1 (4.2) 0 (0) 1 (0.7) 0 (0) 0 (0)
NODE, n (%)
positive 1 (1.8) 14 (58.3) 144 (48.8) 43 (31.9) 0 (0) 23 (48.0)
negative 54 (98.2) 9 (37.5) 151 (51.2) 86 (63.7) 286 (100) 24 (50.0)
missing 0 (0) 1 (4.2) 0 (0) 6 (4.4) 0(0) 1 (2.0)
TUMOR SUBTYPES, n (%)
normal 4 (7.3) 1 (4.2) 8 (2.7) 13 (9.6) 15 (5.2) 1 (2.0)
LumA 23 (41.8) 6 (25.0) 167 (56.6) 59 (43.7) 138 (48.3) 17 (35.4)
LumB 9 (16.4) 9 (37.5) 51 (17.3) 25 (18.5) 51 (17.8) 8 (16.7)
Her2 7 (12.7) 3 (12.5) 23 (7.8) 21 (15.6) 29 (10.1) 9 (18.8)
Basal 12 (21.8) 5 (20.8) 46 (15.6) 17 (12.6) 53 (18.5) 13 (27.1)
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2in our platform and in the 55 paired sample dataset.
The 70-probe signature contains 60 unique genes, and
95% of these (57 of 60) were on our array. Implementa-
tion of the 70 gene good/poor prognosis and 21-gene
recurrence assays on NKI data resulted in highly signifi-
cant prognosis predictions (Additional File 7, Figure S4)
suggesting that the current dataset represents tumors
with similar clinical characteristics as previous tumor
datasets. Applying the PAM50 to the 55 tumor samples
gave representatives of all five subtypes, while the paired
normal tissue was predominantly of normal-like subtype.
A small percentage of non-normal-like subtype speci-
mens was expected based on previous studies that have
shown up to 10% of histologically normal specimens
from cancer patients may have invasive-like signatures
[11]. Of 55 histologically normal samples, 48 (87%) were
Normal-like, 6 (11%) were Luminal A, and 1 (2%) was
Basal-like. Jackknife distances revealed that the sample
with Basal-like subtype was a statistical outlier, suggest-
ing that this normal sample may have had occult con-
tamination with malignant cells that were not identified
by pathologist review. The clinical relevance of normal
tissue with invasive-like signatures is not established,
but it is clear that some genes that are expressed in
tumors are also variable in normal tissue.
We next defined a prototypical normal signature that
could be used in the absence of a paired normal genomic
profile to study the robustness of PAM50 genomic predic-
tion for a given sample. To be used as a prototypical signa-
ture, expression must represent the majority of normal
samples, thus we selected the 48 samples (representing
approximately 90% of samples) that were classified as
Normal-like; the prototypical normal was defined as the
median gene expression across these Normal-like samples.
The observation that some histologically normal tumors
may be classified as invasive tumors using genomic predic-
tors has been reported previously [11], so we also consid-
ered a prototypical normal based on the median of all 55
samples; at the 30% correction rate, the PAM50 subtype
and ROR-S was identical for all samples in the NKI295.
The correlation between the two prototypical normal pro-
files was 0.999. Thus, because the meaning of an invasive-
like signature in adjacent non-neoplastic tissue is still
poorly understood, we used a prototypical signature based
on the 48 normal-like samples to perform adjustments.
Using a value of a that represents the percentage of malig-
nant cells in the tumor sample, we can rearrange equation
1, and subtract the effects of normal tissue (1-a) to obtain
a corrected tumor signature:
log2

R
G

tumor,i
=

log2

R
G

mixed,i
− log2

R
G

normal,i
· (1 − a)

÷ a (2)
For the UNC24 dataset, a was set to equal the percen-
tage of malignant nuclei in the sample. For the public
datasets, we applied a single value of a for all tumors in
a given dataset, with a chosen to maximize negative pre-
dictive value, while also ensuring that all ROR-S cate-
gories had sufficient samp l es i z et op r o v i d es t a b l e
survival analyses. Analyses of the UNC24 dataset were
performed in an attempt to identify gene sets that could
be used to predict percent normal in independent data
and we evaluated a published percent normal signature
[23], but neither had predictive accuracy in independent
test sets, suggesting that while gene sets can be identi-
fied that distinguish normal from tumor, identification
of gene sets that quantitatively estimate percentage nor-
mal is a more challenging problem. In the absence of a
genomic method for estimating percent normal, we
used pathologist assessment where available, or selected
au n i f o r mv a l u eo fa across each dataset/population.
With the latter method there is potential to ‘over-adjust’
or ‘under-adjust’ individual tumors, however the number
of tumors that are adjusted ‘more than necessary’ will be
approximately equal to those that are adjusted ‘less than
necessary’. Thus, despite the lack of individual-level
tumor purity data in most public dataset, the overall
population effects and survival estimates are well
approximated and the population-level results illustrate
the vulnerability of tumor prognostics to normal con-
tamination. Furthermore, the estimated a values selected
for each dataset are correlated with the reported quality
control standards (see Results) for each dataset, suggest-
ing validity of this approach.
Survival analysis
Among the 295 patients with primary breast carcinoma
in the NKI dataset, 151 were lymph node-negative and
36% of these node-negative individuals developed distant
metastasis. For the Naderi et al. [13] and Wang et al.
[12] datasets, 86 and 286 patients had lymph node-nega-
tive disease, respectively, from which 27.9% and 37.4%
developed distant metastasis. We used PAM50 to clas-
sify all node-negative patients as low, medium or high
risk of relapse (ROR-S) and compared these classifica-
tions to their metastasis event occurrences. For the NKI
dataset 50 of 50 genes in the PAM50 were on the array.
Likewise for Naderi et al. [13] and for Wang et al. [12],
48 and 44 of the PAM50 genes were available. We used
the Survival package in R to perform univariate survival
analyses (Kaplan-Meier Analyses).
Sensitivity and negative predictive value
We used the sensitivity and negative predictive value
(NPV) to evaluate the performance of PAM50 as a bin-
ary classifier of risk of relapse. We defined sensitivity as
the probability of receiving a high or medium risk of
relapse score (ROR-S), given relapse occurred by 5
years, by 10 years, or by the end of follow up. Negative
Elloumi et al. BMC Medical Genomics 2011, 4:54
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Page 10 of 12predictive value was defined as probability of remaining
disease free at a particular time point or at the end of
follow up (overall) given a low risk score. The focus of
the study was on sensitivity and NPV because these
tests are used to guide decisions about chemotherapy
and sensitivity (to detect those who will relapse) and
negative predictive value (to identify patients who will
not relapse) are the highest priority [33].
Additional material
Additional file 1: Genes box plots for 48 tumor-adjacent samples
with normal-like subtype. Genes box plots for 48 tumor-adjacent
samples with normal-like subtype. Genes are grouped according to their
use in identifying breast cancer subtypes (i.e. 10 genes used to calculate
Luminal A score together).
Additional file 2: PAM50 classification for the 55 patients assuming
up to 50% contamination in Equation 1. In A, we used the paired
adjacent normal sample to perform the linear combinations and in B, the
prototypical PAM50 normal signature was used in linear combinations.
The PAM50 predictor was applied to the calculated gene expression
under equation 1 in both scenarios. The agreement between A and B
suggest that a prototypical normal signature can be used study the
sensitivity of the PAM50 to normal contamination.
Additional file 3: Effect of correction for percentage normal in
samples with known % normal. Five of 24 samples had original
subtype classifications that differed from those after correction for
percentage normal determined with nuclei counts.
Additional file 4: Supplementary Data 1 showing sensitivity and
negative predictive value at 10 years and to end of follow up.
Sensitivity and negative predictive values are given for 10-year and
relapse-free survival at the end of follow up for NKI, Naderi, and Wang
datasets.
Additional file 5: Overall survival plots for PAM50 ROR-S score,
adjusted and unadjusted. Overall survival plots for PAM50 ROR-S score
given (A) Unadjusted NKI, (B) 30% normal-adjusted NKI and (C) Unadjusted
Naderi et al., (D) 20% correction rate in Naderi et al. Corrections to the
expression assuming a given percentage of tumor were calculated using
equation 2. In each figure, the green line is low ROR-S, the light blue line
is medium ROR-S and the red line is high ROR-S.
Additional file 6: Use of cell lines to test assumption of linear and
symmetrical influence of epithelium and stroma on transcript
abundance. Expression data from pure populations of cancer cells
grown in monoculture were linearly combined with expression data
from pure populations of breast fibroblasts; expected expression values
for ratios of epithelium to stroma equal to 3:1, 2:1 or 1:1 were computed.
These computed values were compared to observed gene expression for
cocultured cells where the actual percentage of epithelial content was
75%, 66% purity, or 50%, respectively. All data for these analyses are
available in the Gene Expression Omnibus, GSE22384) and described in
Camp et al. [32]. Supplemental Table 2 shows that the correlations
between observed and computed were high (0.80-0.92) and that the
slopes were very close to 1.
Additional file 7: Survival plots, unadjusted for normal
contamination. Survivals plots for (A) PAM50, (B) Prognosis method and
(C) 21-gene assay on NKI node-negative patients, unadjusted for normal
contamination. Consistent with previous findings, all three signatures are
significantly associated with survival.
Acknowledgements
This work was supported by the National Cancer Institute at the National
Institutes of Health, grant numbers (R01 CA138255 and P50 CA58233) and
the University Cancer Research Fund.
Author details
1Lineberger Comprehensive Cancer Center, University of North Carolina at
Chapel Hill, Chapel Hill, NC 27599, USA.
2Curriculum in Molecular Biology
and Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC
27599, USA.
3Department of Pathology and Laboratory Medicine, University
of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
4Department of
Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599,
USA.
5Department of Epidemiology, Gillings School of Global Public Health,
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Authors’ contributions
FE and MAT were responsible for the study design, data collection and
analysis, interpretation of the results, and writing and final approval of the
report. ZH, YL, MLG, and KDA were responsible for the provision of data, and
writing and final approval of the report. JP provided bioinformatics
consultation on application of the published version of the PAM50 and
approved the final report. All authors read and approved the final
manuscript.
Competing interests
The primary and corresponding author (FE and MT) have no financial
relationship with any of the assays described in this paper. Likewise ZH, YL,
MG, KA have no financial relationship with any of the assays described. MT
and JP have an ongoing collaborative relationship with Charles Perou,
corresponding author of several manuscripts on the PAM50 assay and
author of a patent for a commercial version of this assay. JP provided
bioinformatics consultation and is a coauthor on a patent of the commercial
version of the PAM50, however, this manuscript does not assess the
commercial version of the PAM50 or any of the other assays discussed.
Received: 22 February 2011 Accepted: 30 June 2011
Published: 30 June 2011
References
1. van’t Veer LJ, Paik S, Hayes DF: Gene expression profiling of breast cancer:
a new tumor marker. J Clin Oncol 2005, 23(8):1631-1635.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR,
Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast
tumours. Nature 2000, 406(6797):747-752.
3. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T,
Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of
breast carcinomas distinguish tumor subclasses with clinical
implications. Proc Natl Acad Sci USA 2001, 98(19):10869-10874.
4. van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL,
van der Kooy K, Marton MJ, Witteveen AT, et al: Gene expression profiling
predicts clinical outcome of breast cancer. Nature 2002,
415(6871):530-536.
5. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW,
Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al: A gene-expression
signature as a predictor of survival in breast cancer. N Engl J Med 2002,
347(25):1999-2009.
6. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG,
Watson D, Park T, et al: A multigene assay to predict recurrence of
tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004,
351(27):2817-2826.
7. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL,
Watson D, Bryant J, et al: Gene expression and benefit of chemotherapy
in women with node-negative, estrogen receptor-positive breast cancer.
J Clin Oncol 2006, 24(23):3726-3734.
8. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S,
Fauron C, He X, Hu Z, et al: Supervised risk predictor of breast cancer
based on intrinsic subtypes. J Clin Oncol 2009, 27(8):1160-1167.
9. Troester MA, Lee MH, Carter M, Fan C, Cowan DW, Perez ER, Pirone JR,
Perou CM, Jerry DJ, Schneider SS: Activation of host wound responses in
breast cancer microenvironment. Clin Cancer Res 2009, 15(22):7020-7028.
10. Piantadosi S: Random error and bias. In Clinical Trials. Edited by: Piantadosi
S. Wiley 2005:167-186.
11. Chen DT, Nasir A, Culhane A, Venkataramu C, Fulp W, Rubio R, Wang T,
Agrawal D, McCarthy SM, Gruidl M, et al: Proliferative genes dominate
malignancy-risk gene signature in histologically-normal breast tissue.
Breast Cancer Res Treat 2009.
Elloumi et al. BMC Medical Genomics 2011, 4:54
http://www.biomedcentral.com/1755-8794/4/54
Page 11 of 1212. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D,
Timmermans M, Meijer-van Gelder ME, Yu J, et al: Gene-expression profiles
to predict distant metastasis of lymph-node-negative primary breast
cancer. Lancet 2005, 365(9460):671-679.
13. Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR,
Powe DG, Robertson JF, Aparicio S, Ellis IO, Brenton JD, et al: A gene-
expression signature to predict survival in breast cancer across
independent data sets. Oncogene 2007, 26(10):1507-1516.
14. Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, Jones C,
Lord CJ, Vatcheva R, Rodriguez-Pinilla SM, et al: An integrative genomic
and transcriptomic analysis reveals molecular pathways and networks
regulated by copy number aberrations in basal-like, HER2 and luminal
cancers. Breast Cancer Res Treat 2009.
15. Venet D, Pecasse F, Maenhaut C, Bersini H: Separation of samples into
their constituents using gene expression data. Bioinformatics 2001,
17(Suppl 1):S279-287.
16. Tureci O, Ding J, Hilton H, Bian H, Ohkawa H, Braxenthaler M, Seitz G,
Raddrizzani L, Friess H, Buchler M, et al: Computational dissection of tissue
contamination for identification of colon cancer-specific expression
profiles. Faseb J 2003, 17(3):376-385.
17. Lu P, Nakorchevskiy A, Marcotte EM: Expression deconvolution: a
reinterpretation of DNA microarray data reveals dynamic changes in cell
populations. Proc Natl Acad Sci USA 2003, 100(18):10370-10375.
18. Wang M, Master SR, Chodosh LA: Computational expression
deconvolution in a complex mammalian organ. BMC Bioinformatics 2006,
7:328.
19. Hoffmann M, Pohlers D, Koczan D, Thiesen HJ, Wolfl S, Kinne RW: Robust
computational reconstitution - a new method for the comparative
analysis of gene expression in tissues and isolated cell fractions. BMC
Bioinformatics 2006, 7:369.
20. Lahdesmaki H, Shmulevich L, Dunmire V, Yli-Harja O, Zhang W: In silico
microdissection of microarray data from heterogeneous cell populations.
BMC Bioinformatics 2005, 6:54.
21. Gosink MM, Petrie HT, Tsinoremas NF: Electronically subtracting
expression patterns from a mixed cell population. Bioinformatics 2007,
23(24):3328-3334.
22. Ghosh D: Mixture models for assessing differential expression in
complex tissues using microarray data. Bioinformatics 2004,
20(11):1663-1669.
23. Cleator SJ, Powles TJ, Dexter T, Fulford L, Mackay A, Smith IE, Valgeirsson H,
Ashworth A, Dowsett M: The effect of the stromal component of breast
tumours on prediction of clinical outcome using gene expression
microarray analysis. Breast Cancer Res 2006, 8(3):R32.
24. Fuller AP, Palmer-Toy D, Erlander MG, Sgroi DC: Laser capture
microdissection and advanced molecular analysis of human breast
cancer. J Mammary Gland Biol Neoplasia 2003, 8(3):335-345.
25. Chu TY, Hwang KS, Yu MH, Lee HS, Lai HC, Liu JY: A research-based tumor
tissue bank of gynecologic oncology: characteristics of nucleic acids
extracted from normal and tumor tissues from different sites. Int J
Gynecol Cancer 2002, 12(2):171-176.
26. Weigelt B, Mackay A, A’Hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A,
Reis-Filho JS: Breast cancer molecular profiling with single sample
predictors: a retrospective analysis. Lancet Oncol 11(4):339-349.
27. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD: Pivotal evaluation of the
accuracy of a biomarker used for classification or prediction: standards
for study design. J Natl Cancer Inst 2008, 100(20):1432-1438.
28. Andre F, Delaloge S: First-generation genomic tests for breast cancer
treatment. Lancet Oncol 11(1):6-7.
29. Robb JA, Moore HM, Compton CC: Documenting biospecimen conditions
in reports of studies. Jama 2008, 300(6):650-651, author reply 651.
30. Fitzgibbons PL, Murphy DA, Hammond ME, Allred DC, Valenstein PN:
Recommendations for validating estrogen and progesterone receptor
immunohistochemistry assays. Arch Pathol Lab Med 134(6):930-935.
31. Jennings L, Van Deerlin VM, Gulley ML: Recommended principles and
practices for validating clinical molecular pathology tests. Arch Pathol Lab
Med 2009, 133(5):743-755.
32. Camp JT, Elloumi F, Roman-Perez E, Rein J, Stewart DA, Harrell JC,
Perou CM, Troester MA: Interactions with fibroblasts are distinct in Basal-
like and luminal breast cancers. Mol Cancer Res 9(1):3-13.
33. Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, Dahiya S,
Habin K, Bernards R, Haber DA, et al: Analysis of the MammaPrint breast
cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res
2008, 14(10):2988-2993.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1755-8794/4/54/prepub
doi:10.1186/1755-8794-4-54
Cite this article as: Elloumi et al.: Systematic Bias in Genomic
Classification Due to Contaminating Non-neoplastic Tissue in Breast
Tumor Samples. BMC Medical Genomics 2011 4:54.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Elloumi et al. BMC Medical Genomics 2011, 4:54
http://www.biomedcentral.com/1755-8794/4/54
Page 12 of 12